KOD Kodiak Pharma Earnings per share for the last twelve months

KOD (Kodiak Corp) - company brandmark

The EPS TTM history on GURU.Markets shows that the parameter has settled at -4.06, while Kodiak Sciences Inc. (KOD) faces a liquidity shortage due to testing costs. The complexity of certifying ophthalmological agents limits the pool of competitors. However, the success of the ABC platform and FDA approval will grant the company monopoly status and colossal profits.

KOD Kodiak Sciences Inc. Net earnings per share (EPS TTM) (07/04/2022 - 11/18/2026)

Financial and market metric breakdowns for Kodiak Pharma (KOD)

- stock price and consensus target price:
Fundamental company analysis:kodiak.com (KOD)
Manufactured products of Kodiak Sciences Inc

To minimize fundamental risks, investors should select assets with sustainable net income per common share dynamics over the last 12 months. This metric reflects real capital generation efficiency, which is critical for Kodiak Sciences Inc. (KOD) given the high costs of outsourcing ophthalmological research; any sharp fluctuations in the rolling annual EPS trend signal a change in operating profitability.

Competitors of Kodiak Sciences Inc. (KOD)